PROFOUND MEDICAL CORP (PROF) Fundamental Analysis & Valuation

NASDAQ:PROF • CA74319B5027

Current stock price

5.855 USD
+0.15 (+2.54%)
Last:

This PROF fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. PROF Profitability Analysis

1.1 Basic Checks

  • In the past year PROF has reported negative net income.
  • PROF had a negative operating cash flow in the past year.
  • In the past 5 years PROF always reported negative net income.
  • PROF had a negative operating cash flow in each of the past 5 years.
PROF Yearly Net Income VS EBIT VS OCF VS FCFPROF Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • PROF's Return On Assets of -54.95% is on the low side compared to the rest of the industry. PROF is outperformed by 67.93% of its industry peers.
  • PROF has a Return On Equity of -64.08%. This is comparable to the rest of the industry: PROF outperforms 45.65% of its industry peers.
Industry RankSector Rank
ROA -54.95%
ROE -64.08%
ROIC N/A
ROA(3y)-53.2%
ROA(5y)-47.9%
ROE(3y)-67.25%
ROE(5y)-58.99%
ROIC(3y)N/A
ROIC(5y)N/A
PROF Yearly ROA, ROE, ROICPROF Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -20 -40 -60 -80 -100

1.3 Margins

  • With an excellent Gross Margin value of 70.77%, PROF belongs to the best of the industry, outperforming 80.43% of the companies in the same industry.
  • In the last couple of years the Gross Margin of PROF has grown nicely.
  • The Profit Margin and Operating Margin are not available for PROF so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 70.77%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.11%
GM growth 5Y8.27%
PROF Yearly Profit, Operating, Gross MarginsPROF Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -200 -400 -600

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. PROF Health Analysis

2.1 Basic Checks

  • PROF does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • PROF has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, PROF has more shares outstanding
  • PROF has a better debt/assets ratio than last year.
PROF Yearly Shares OutstandingPROF Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M
PROF Yearly Total Debt VS Total AssetsPROF Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 5.60 indicates that PROF is not in any danger for bankruptcy at the moment.
  • PROF has a better Altman-Z score (5.60) than 80.43% of its industry peers.
  • A Debt/Equity ratio of 0.07 indicates that PROF is not too dependend on debt financing.
  • PROF has a Debt to Equity ratio of 0.07. This is in the better half of the industry: PROF outperforms 67.39% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Altman-Z 5.6
ROIC/WACCN/A
WACC9.16%
PROF Yearly LT Debt VS Equity VS FCFPROF Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M 60M 80M

2.3 Liquidity

  • A Current Ratio of 12.52 indicates that PROF has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 12.52, PROF belongs to the top of the industry, outperforming 96.74% of the companies in the same industry.
  • A Quick Ratio of 11.17 indicates that PROF has no problem at all paying its short term obligations.
  • PROF's Quick ratio of 11.17 is amongst the best of the industry. PROF outperforms 96.74% of its industry peers.
Industry RankSector Rank
Current Ratio 12.52
Quick Ratio 11.17
PROF Yearly Current Assets VS Current LiabilitesPROF Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

6

3. PROF Growth Analysis

3.1 Past

  • The earnings per share for PROF have decreased strongly by -25.89% in the last year.
  • Looking at the last year, PROF shows a very strong growth in Revenue. The Revenue has grown by 44.36%.
  • Measured over the past years, PROF shows a quite strong growth in Revenue. The Revenue has been growing by 17.12% on average per year.
EPS 1Y (TTM)-25.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35%
Revenue 1Y (TTM)44.36%
Revenue growth 3Y34.06%
Revenue growth 5Y17.12%
Sales Q2Q%43.09%

3.2 Future

  • Based on estimates for the next years, PROF will show a very strong growth in Earnings Per Share. The EPS will grow by 28.18% on average per year.
  • Based on estimates for the next years, PROF will show a very strong growth in Revenue. The Revenue will grow by 72.73% on average per year.
EPS Next Y23.59%
EPS Next 2Y23%
EPS Next 3Y24.93%
EPS Next 5Y28.18%
Revenue Next Year101.18%
Revenue Next 2Y79.76%
Revenue Next 3Y65.72%
Revenue Next 5Y72.73%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PROF Yearly Revenue VS EstimatesPROF Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M
PROF Yearly EPS VS EstimatesPROF Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

1

4. PROF Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PROF. In the last year negative earnings were reported.
  • Also next year PROF is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PROF Price Earnings VS Forward Price EarningsPROF Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PROF Per share dataPROF EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

  • PROF's earnings are expected to grow with 24.93% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23%
EPS Next 3Y24.93%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PROF Dividend Analysis

5.1 Amount

  • No dividends for PROF!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PROF Fundamentals: All Metrics, Ratios and Statistics

PROFOUND MEDICAL CORP

NASDAQ:PROF (3/17/2026, 11:57:08 AM)

5.855

+0.15 (+2.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)03-05
Earnings (Next)05-06
Inst Owners45.42%
Inst Owner Change36.7%
Ins Owners11.81%
Ins Owner Change0%
Market Cap212.48M
Revenue(TTM)16.10M
Net Income(TTM)-42.57M
Analysts80
Price Target11.6 (98.12%)
Short Float %4.8%
Short Ratio6
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)14.61%
Min EPS beat(2)-0.25%
Max EPS beat(2)29.47%
EPS beat(4)1
Avg EPS beat(4)-9.54%
Min EPS beat(4)-40.1%
Max EPS beat(4)29.47%
EPS beat(8)4
Avg EPS beat(8)-1.56%
EPS beat(12)7
Avg EPS beat(12)-0.4%
EPS beat(16)10
Avg EPS beat(16)3.17%
Revenue beat(2)1
Avg Revenue beat(2)-6.67%
Min Revenue beat(2)-18.19%
Max Revenue beat(2)4.86%
Revenue beat(4)1
Avg Revenue beat(4)-19.31%
Min Revenue beat(4)-38.03%
Max Revenue beat(4)4.86%
Revenue beat(8)1
Avg Revenue beat(8)-15.36%
Revenue beat(12)2
Avg Revenue beat(12)-15.18%
Revenue beat(16)3
Avg Revenue beat(16)-17.16%
PT rev (1m)2.04%
PT rev (3m)2.83%
EPS NQ rev (1m)-4.17%
EPS NQ rev (3m)5.66%
EPS NY rev (1m)-8.48%
EPS NY rev (3m)-2.56%
Revenue NQ rev (1m)-18.92%
Revenue NQ rev (3m)-18.92%
Revenue NY rev (1m)-7.21%
Revenue NY rev (3m)-7.21%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 13.2
P/FCF N/A
P/OCF N/A
P/B 3.2
P/tB 3.2
EV/EBITDA N/A
EPS(TTM)-1.41
EYN/A
EPS(NY)-1.08
Fwd EYN/A
FCF(TTM)-1.06
FCFYN/A
OCF(TTM)-1.05
OCFYN/A
SpS0.44
BVpS1.83
TBVpS1.83
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -54.95%
ROE -64.08%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 70.77%
FCFM N/A
ROA(3y)-53.2%
ROA(5y)-47.9%
ROE(3y)-67.25%
ROE(5y)-58.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y16.11%
GM growth 5Y8.27%
F-Score4
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.07
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 43.21%
Cap/Sales 1.5%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.52
Quick Ratio 11.17
Altman-Z 5.6
F-Score4
WACC9.16%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-25.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35%
EPS Next Y23.59%
EPS Next 2Y23%
EPS Next 3Y24.93%
EPS Next 5Y28.18%
Revenue 1Y (TTM)44.36%
Revenue growth 3Y34.06%
Revenue growth 5Y17.12%
Sales Q2Q%43.09%
Revenue Next Year101.18%
Revenue Next 2Y79.76%
Revenue Next 3Y65.72%
Revenue Next 5Y72.73%
EBIT growth 1Y-26.29%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year32.1%
EBIT Next 3Y37.89%
EBIT Next 5Y35.42%
FCF growth 1Y-63.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-62.91%
OCF growth 3YN/A
OCF growth 5YN/A

PROFOUND MEDICAL CORP / PROF Fundamental Analysis FAQ

What is the fundamental rating for PROF stock?

ChartMill assigns a fundamental rating of 4 / 10 to PROF.


Can you provide the valuation status for PROFOUND MEDICAL CORP?

ChartMill assigns a valuation rating of 1 / 10 to PROFOUND MEDICAL CORP (PROF). This can be considered as Overvalued.


What is the profitability of PROF stock?

PROFOUND MEDICAL CORP (PROF) has a profitability rating of 2 / 10.


How financially healthy is PROFOUND MEDICAL CORP?

The financial health rating of PROFOUND MEDICAL CORP (PROF) is 6 / 10.